Advances in Targeted Therapy for Systemic Lupus Erythematosus: Current Treatments and Novel Approaches
International Journal of Molecular Sciences · 23.01.2025 · 26 (3) · 929
DOI: 10.3390/ijms26030929 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.01.2025. Verfasst von Kazusa Saegusa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Molecular Targeted Therapy. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical manifestations that can lead to severe organ damage. The complex pathophysiology of SLE makes treatment selection difficult. This review examines the current evidence for biological therapies in SLE, including the anti-B cell activating factor antibody belimumab; the type I interferon receptor antagonist anifrolumab; the novel calcineurin inhibitor voclosporin; and rituximab, which targets CD20 on B cells. We also describe emerging therapies, including novel agents in development and CD19-directed chimeric antigen receptor (CAR) T cell therapy, which has shown promise in early clinical experience. Recent advances in biomarker research, including interferon signatures and transcriptomic profiles, may facilitate patient stratification and treatment selection. This review offers insights into current and future treatment strategies for patients with SLE by analyzing clinical trial results and recent immunological findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
ORCID-Profile: Kazusa Saegusa, Yumi Tsuchida, Toshihiko Komai, Keishi Fujio
Förderung
- Japan Science and Technology Agency
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Center of Innovation Program from Japan Science and Technology Agency (JST)
- Ministry of Education, Culture, Sports, and the Japan Agency for Medical Research and Development (AMED)
- Ministry of Education, Culture, Sports, and the AMED
- Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C)
Zitieren
APA
Saegusa, K., Tsuchida, Y., Komai, T., Tsuchiya, H., & Fujio, K. (2025). Advances in Targeted Therapy for Systemic Lupus Erythematosus: Current Treatments and Novel Approaches. International Journal of Molecular Sciences, 26(3), 929. https://doi.org/10.3390/ijms26030929
Vancouver
Saegusa K, Tsuchida Y, Komai T, Tsuchiya H, Fujio K. Advances in Targeted Therapy for Systemic Lupus Erythematosus: Current Treatments and Novel Approaches. International Journal of Molecular Sciences. 2025;26(3):929. doi:10.3390/ijms26030929
BibTeX
@article{Saegusa2025,
author = {Saegusa, Kazusa and Tsuchida, Yumi and Komai, Toshihiko and Tsuchiya, Haruka and Fujio, Keishi},
title = {Advances in Targeted Therapy for Systemic Lupus Erythematosus: Current Treatments and Novel Approaches},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {3},
pages = {929},
doi = {10.3390/ijms26030929}
}
EUVIMED